JPMorgan Healthcare Leaders ETF
JDOC - ETF AI Analysis
Top Page
JPMorgan Healthcare Leaders ETF (JDOC)
JDOC, the JPMorgan Healthcare Leaders ETF, is built around high-quality healthcare giants like Merck, Novartis, Johnson & Johnson, and AstraZeneca, whose strong financial performance, solid pipelines, and positive earnings outlooks are key drivers of the fund’s solid overall rating. These strengths are partly offset by risks such as high valuations, leverage and cash flow challenges in names like Eli Lilly, Thermo Fisher, and UnitedHealth, plus some bearish or overbought technical signals, which add volatility and temper the fund’s appeal. The main risk factor is the ETF’s concentration in the healthcare sector, meaning its performance is closely tied to industry-specific trends and regulatory developments.
JDOC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 10.02M
- Region
- Global
- Expense Ratio
- 0.65%
- Beta
- 0.45
- Issuer
- JPMorgan
- Inception Date
- Nov 01, 2023
- Dividend Yield
- 0.76%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
JDOC Summary
JDOC, the JPMorgan Healthcare Leaders ETF, focuses on the global healthcare theme rather than tracking a specific index. It invests mainly in U.S. healthcare companies, including well-known names like Johnson & Johnson and Eli Lilly, along with drug makers, medical device firms, and health insurance providers. Someone might invest in JDOC to tap into long-term growth driven by aging populations, new medicines, and rising healthcare spending, while still spreading money across many companies in the sector. A key risk is that it is heavily concentrated in healthcare, so its value can rise or fall sharply if that sector has problems.
How much will it cost me?
This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed and focused on a specialized healthcare sector, which typically costs more to run than broad, passive index funds.
What would affect this ETF?
JDOC could benefit from aging populations, rising global healthcare spending, and continued innovation in drugs and medical technology from major holdings like AbbVie, Eli Lilly, and Johnson & Johnson. On the downside, changes in government healthcare policies, drug pricing rules, or global economic slowdowns could hurt profits for large insurers and pharmaceutical companies such as UnitedHealth and Merck, which would weigh on the ETF’s performance.
JDOC Top 10 Holdings
JDOC is leaning heavily on big pharma and healthcare giants, with AbbVie, Eli Lilly, and Johnson & Johnson doing most of the heavy lifting as their shares keep rising and sentiment stays upbeat. UnitedHealth and Thermo Fisher add steady, growth-oriented exposure, though UnitedHealth’s recent stretch has been more mixed. Merck is another quiet engine, contributing solidly despite occasional bumps. On the weaker side, AstraZeneca and Intuitive Surgical have been lagging, occasionally acting as a brake on returns. Overall, it’s a globally diversified but clearly healthcare-focused portfolio anchored in large, established names.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 8.73% | $881.06K | $1.36T | 41.12% | 72Outperform | |
| AbbVie | 8.35% | $843.05K | $521.50B | 27.01% | 66Neutral | |
| UnitedHealth | 5.24% | $529.06K | $365.09B | 22.54% | 72Outperform | |
| Johnson & Johnson | 4.69% | $473.61K | $687.89B | 46.35% | 78Outperform | |
| Novartis AG | 4.50% | $454.50K | CHF 245.40B | 26.78% | 80Outperform | |
| Thermo Fisher | 4.42% | $446.42K | $259.44B | 20.70% | 72Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| Merck & Company | 3.51% | $354.26K | $364.26B | 59.00% | 80Outperform | |
| Danaher | 2.85% | $287.78K | $163.94B | 5.34% | 75Outperform | |
| Intuitive Surgical | 2.63% | $265.22K | $153.77B | -21.56% | 78Outperform |
JDOC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JDOC, the sentiment is Positive. The current price of 67.25 is above the 20-day moving average (MA) of 65.35, above the 50-day MA of 62.73, and above the 200-day MA of 59.40, indicating a bullish trend. The MACD of 1.43 indicates Negative momentum. The RSI at 66.61 is Neutral, neither overbought nor oversold. The STOCH value of 82.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JDOC.
JDOC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $67.25 | $65.00(-3.35% Downside) | $10.02M | 0.65% | 66Neutral | |
| $36.34 | $46.47(27.88% Upside) | $44.15M | 0.80% | 62Neutral | |
| $34.80 | $54.70(57.19% Upside) | $41.60M | 0.44% | 60Neutral | |
| $38.01 | $44.46(16.98% Upside) | $17.77M | 0.85% | 65Neutral | |
| $36.32 | $40.35(11.10% Upside) | $14.56M | 0.55% | 65Neutral | |
| $26.09 | $38.81(48.74% Upside) | $11.14M | 0.75% | 55Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JDOC | JPMorgan Healthcare Leaders ETF | 67.25 | 10.66 | 18.84% | |
| MEDI | Harbor Health Care ETF | 36.34 | 4.91 | 15.61% | |
| TMED | T. Rowe Price Health Care ETF | 34.80 | 5.80 | 19.98% | |
| MEDX | Horizon Kinetics Medical ETF | 38.01 | 5.59 | 17.25% | |
| BMED | Future Health ETF | 36.32 | 7.37 | 25.46% | |
| HLTH | Tema Healthcare AI ETF | 26.09 | 0.78 | 3.09% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
